LivingGLP1
crossover randomized trial

S003151

Design

Randomized
24
Start year
Treatment
Countries
Germany
Sponsor
(mixed)
Eligibility
obese nondiabetic right handed nonsmoking Caucasian men; BMI 30 to 46 observed

Conduct and analysis

Blinding
double blind
Sequence generation
not reported
Allocation concealment
not reported
Outcome adjudication
not reported
Primary estimand
not stated
Analysis population
Missing data

Arms

ArmTreatmentBackgroundRandomizedAnalyzedCompleted treatment
A1Placebo
Placebo infusion
lifestyle: not reported2424
A2exenatide
Exenatide infusion
lifestyle: not reported2424

Baseline characteristics

As printed in the trial reports or registry, per arm or for the whole trial.
CharacteristicStatisticPlacebo
A1
Exenatide infusion
A2
Whole trial
ALL
agemax (years)43
agemean (years)29
agemin (years)18
agesd (years)7
bmimax (kg/m2)46
bmimean (kg/m2)37
bmimin (kg/m2)30
bmisd (kg/m2)5
other malen24
weightmax (kg)155
weightmean (kg)120
weightmin (kg)91
weightsd (kg)18
whiten24